Luis Merchan: Yes. I’ll provide some strategic update, and then I’ll allow Elshad to provide the mechanics and the financials. But you’re absolutely right. We completed that acquisition in the latter part of December. And the integration is still ongoing, of course. We feel strongly about not only what that company brings in terms of our ability to distribute cannabis into Germany and the European market but as well as the distribution of that network that it has set up in 28 countries across the globe. They have a top pharmaceutical team distribution team that has done this for a number of decades and have a know-how and the experience to move cannabis across the supply chain. Their Founder and CEO, of course, is now President of Flora.
His name is Clifford Starke. He joined our Board of Directors, and he’s been instrumental in the integration of the company. And he is also supporting our commercial wholesale operation now to ensure that we can move cannabis across the supply chain internationally. I believe this acquisition is a meaningful long clock for us, and we’re going to see the results of it in the upcoming months and quarters. Elshad?
Elshad Garayev: Yes, sure. I want to complement and maybe a quick reminder in terms of – this was a stock acquisition paid by Flora stock. We issued close to 43,525,951 million shares to be exact. And in terms of what that turned to in terms of purchase price allocation with 7.5 million discount for marketability. We recorded net asset value in books $9.8 million. $9.8 million represents breakdown between $6.1 million net identifiable assets, which was booked in our balance sheet, as well as $3.7 million of goodwill. As Luis, it’s 8 to 7 days operation, but I’m very happy that from day one, that team fully integrated into our operations. For example, one of my senior deputies, Daniel Ramon stepped in into our finance organization, as well as the leadership of our Germany-based operation has been part of our operating and sport network.
We’re actively working, integrating and I can – with FGH and also applying best practices like we believe they have a more robust ERP system, which we are leveraging. So has been – it’s still a process ongoing as we go through New Year, we look forward capitalizing on those synergies.
Jessie Casner: Thanks, Luis. Thanks, Elshad. We are just a little bit over on time, but we did get a question from Marla Marin from Zack, and I just wanted to quickly answer that. So she talked about the time line around some of the clinical trials and research that we’re doing. And so just an update there? As I had mentioned, any pharmaceutical pillar update. We are just awaiting approval from the NHS as well as the MHRA. And so all of our required paperwork is in, all of the preclinical work has been done. As many of you might be aware, the NHS is not only the governing body that would approve a clinical trial, but they also administer all health care within the country. And so these things as government agencies tend to happen to take a little bit of time.
So we’ll continue to update. I would remind everybody that we are moving to quarterly reporting, and so we’ll be able to provide more updates on a pillar-by-pillar basis and give everybody a little bit more transparency, as Elshad mentioned, with our new filings and structure.
Jessie Casner: So with that, again, like I said, we are a little bit over on time. So that draws to a close our earnings call for the full year 2022, and we appreciate everybody for attending. Thank you, Luis. Thank you, Elshad.
Elshad Garayev: Thank you.
Luis Merchan: Good day, everyone.
